In a systematic review containing a meta-analyze, three novel AD biomarkers defined as β-2-glycoprotein, ApoA-1, and α-2-macroglobulin (α2 M), were reported to be detected in the CSF (Rehiman et al., 2020). This evidence concerns the gene A2M and Alzheimer disease.